Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
AbbVie
M.D. Anderson Cancer Center
I-Mab Biopharma US Limited
Beth Israel Deaconess Medical Center
Tesaro, Inc.
Sotio Biotech Inc.
Wake Forest University Health Sciences
Corcept Therapeutics
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Leap Therapeutics, Inc.
Tesaro, Inc.
Tesaro, Inc.
Universitaire Ziekenhuizen KU Leuven
Mayo Clinic
Thomas Jefferson University
M.D. Anderson Cancer Center
Elevation Oncology
Aprea Therapeutics
AstraZeneca
Mario Negri Institute for Pharmacological Research
North Eastern German Society of Gynaecological Oncology
Mayo Clinic
Roswell Park Cancer Institute
Astex Pharmaceuticals, Inc.
University of Pittsburgh
National Cancer Institute (NCI)
Takeda
Takeda
Exelixis
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Albert Einstein College of Medicine
Medical College of Wisconsin
Northwestern University
Ludwig Institute for Cancer Research
pharmaand GmbH
Merck Sharp & Dohme LLC
University of Wisconsin, Madison
Canadian Cancer Trials Group
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
AstraZeneca
OncoNano Medicine, Inc.
Tesaro, Inc.
Gradalis, Inc.